m-Bis(2-cyanoisopropyl)benzol | 59508-34-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: m-Bis(2-cyanoisopropyl)benzol
• 英文别名: 2-[3-(2-Cyanopropan-2-yl)phenyl]-2-methylpropanenitrile
• CAS: 59508-34-8
• 化学式: C₁₄H₁₆N₂
• 分子量: 212.294
• InChiKey: LCULOHYKFKKZEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• APOGOSSYPOLONE AND THE USES THEREOF
  申请人：Wang Shaomeng

  公开号：US20090118377A1

  公开（公告）日：2009-05-07

  The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

  本发明涉及化合物apogossypolone及其盐和前药。Apogossypolone作为Bcl-2家族蛋白的抑制剂。本发明还涉及使用apogossypolone来抑制过度增殖的细胞生长，诱导细胞凋亡以及使细胞对诱导凋亡性细胞死亡更敏感。
• Cancer stem cell vaccination and treatment
  申请人：The Regents of the University of Michigan

  公开号：US10173074B2

  公开（公告）日：2019-01-08

  The present invention relates to methods, systems, and compositions for treating and preventing cancer in a subject with the combination of radiation therapy and antigen presenting cells that have been exposed cancer stem cells or a portion thereof. In certain embodiments, the antigen presenting cells are dendritic cells that have been pulsed with ALDHhigh cancer stem cells.

  本发明涉及结合放射治疗和已暴露癌症干细胞或其部分的抗原呈递细胞治疗和预防受试者癌症的方法、系统和组合物。在某些实施方案中，抗原呈递细胞是用ALDH高的癌症干细胞脉冲的树突状细胞。
• Encapsulated arsenic drugs
  申请人：O'Halloran Thomas

  公开号：US20070065498A1

  公开（公告）日：2007-03-22

  The present invention relates to methods and compositions for the treatment of cancer and for research and analysis of cancer. In particular, the present invention provides encapsulated arsenic anti-cancer compositions with improved properties.
• Methods and compositions for cancer therapy
  申请人：Sheikhnejad Gholamreza

  公开号：US20070213285A1

  公开（公告）日：2007-09-13

  The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
• Growth hormone receptor antagonist cancer treatment
  申请人：Wicha S. Max

  公开号：US20070243192A1

  公开（公告）日：2007-10-18

  The present invention provides methods and compositions for treating tumorigenic cells (e.g., mammary progenitor cancer cells), with growth hormone receptor antagonists (e.g., Pegvisomant), as well as methods and compositions for screening growth hormone receptor antagonists for their ability serve as anti-neoplastic agents capable of killing tumorigenic cells. The present invention provides methods for identifying tumorigenic cells, methods of obtaining enriched populations of tumorigenic cells, and methods of causing mammary progenitor cells to proliferate and/or differentiate.